Spago Nanomedical Toekomstige groei
Future criteriumcontroles 3/6
Spago Nanomedical is forecast to grow earnings and revenue by 60.8% and 105.5% per annum respectively. EPS is expected to grow by 63.5% per annum. Return on equity is forecast to be 20.7% in 3 years.
Belangrijke informatie
60.8%
Groei van de winst
63.5%
Groei van de winst per aandeel
| Biotechs winstgroei | 48.4% |
| Inkomstengroei | 105.5% |
| Toekomstig rendement op eigen vermogen | 20.7% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 02 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Most Shareholders Will Probably Agree With Spago Nanomedical AB (publ)'s (STO:SPAGO) CEO Compensation
Jun 04
We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn
Sep 21We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow
May 26Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven
Mar 30We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely
Feb 03
Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term
Dec 11Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 185 | 33 | 31 | 31 | 1 |
| 12/31/2025 | 14 | -50 | -49 | -49 | 1 |
| 12/31/2024 | 33 | -27 | -24 | -23 | 1 |
| 6/30/2024 | 6 | -33 | -34 | -34 | N/A |
| 3/31/2024 | 6 | -34 | -39 | -39 | N/A |
| 12/31/2023 | 6 | -42 | -45 | -45 | N/A |
| 9/30/2023 | 6 | -43 | -47 | -43 | N/A |
| 6/30/2023 | 6 | -45 | -50 | -48 | N/A |
| 3/31/2023 | 6 | -45 | -48 | -44 | N/A |
| 12/31/2022 | 6 | -39 | -42 | -38 | N/A |
| 9/30/2022 | 6 | -39 | -47 | -43 | N/A |
| 6/30/2022 | 6 | -41 | -47 | -43 | N/A |
| 3/31/2022 | 6 | -43 | -44 | -40 | N/A |
| 12/31/2021 | 6 | -39 | -40 | -36 | N/A |
| 9/30/2021 | 7 | -32 | -35 | -29 | N/A |
| 6/30/2021 | 7 | -27 | -29 | -23 | N/A |
| 3/31/2021 | 7 | -20 | -28 | -22 | N/A |
| 12/31/2020 | 7 | -19 | -25 | -19 | N/A |
| 9/30/2020 | 7 | -20 | -40 | -22 | N/A |
| 6/30/2020 | 13 | -21 | -33 | -21 | N/A |
| 3/31/2020 | 16 | -21 | -37 | -23 | N/A |
| 12/31/2019 | 19 | -20 | -40 | -21 | N/A |
| 9/30/2019 | 25 | -18 | -45 | -16 | N/A |
| 6/30/2019 | 25 | -15 | -40 | -16 | N/A |
| 3/31/2019 | 27 | -13 | -44 | -10 | N/A |
| 12/31/2018 | 30 | -11 | -39 | -11 | N/A |
| 9/30/2018 | 30 | -11 | -19 | -10 | N/A |
| 6/30/2018 | 27 | -10 | -34 | -7 | N/A |
| 3/31/2018 | 23 | -10 | N/A | -9 | N/A |
| 12/31/2017 | 18 | -9 | N/A | -8 | N/A |
| 9/30/2017 | 13 | -8 | N/A | -7 | N/A |
| 6/30/2017 | 12 | -8 | N/A | -7 | N/A |
| 3/31/2017 | 11 | -7 | N/A | -7 | N/A |
| 12/31/2016 | 11 | -8 | N/A | -8 | N/A |
| 9/30/2016 | 9 | -7 | N/A | -7 | N/A |
| 6/30/2016 | 8 | -7 | N/A | -6 | N/A |
| 3/31/2016 | 8 | -7 | N/A | -7 | N/A |
| 12/31/2015 | 8 | -7 | N/A | -5 | N/A |
| 9/30/2015 | 7 | -8 | N/A | -7 | N/A |
| 6/30/2015 | 7 | -7 | N/A | -8 | N/A |
| 3/31/2015 | 7 | -7 | N/A | -7 | N/A |
| 12/31/2014 | 8 | -6 | N/A | -6 | N/A |
| 9/30/2014 | 7 | -7 | N/A | -6 | N/A |
| 6/30/2014 | 9 | -7 | N/A | -5 | N/A |
| 3/31/2014 | 8 | -5 | N/A | -3 | N/A |
| 12/31/2013 | 8 | -5 | N/A | -8 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: SPAGO is forecast to remain unprofitable over the next 3 years.
Winst versus markt: SPAGO is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: SPAGO is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: SPAGO's revenue (105.5% per year) is forecast to grow faster than the Swedish market (0.01% per year).
Hoge groei-inkomsten: SPAGO's revenue (105.5% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: SPAGO's Return on Equity is forecast to be high in 3 years time (20.7%)